Supplementary plain language summary: Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article</b><b> </b><b>'</b><b>Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><p dir="ltr"><b>Plain language summary: A study looking at people living with </b><b>multiple sclerosis who switched from </b><b>treatment with anti-CD20s to fumarates</b></p><ul><li>How to pronounce</li><li>Why was this study done?</li><li>What did researchers want to find out?</li><li>What were the findings from this study?</li><li>What were the main conclusions from this study?</li><li>Who funded this study?</li></ul><p></p>